Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313360294> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4313360294 endingPage "75.5" @default.
- W4313360294 startingPage "75.5" @default.
- W4313360294 abstract "Abstract Activation of an anticancer innate immune response is an attractive immunotherapeutic opportunity that is challenged by insufficient safety of systemically administered innate immune modulators. Unusual tissue specificity of expression of TLR5 determines a uniquely safe profile of cytokines induced by the sole TLR5 agonist flagellin. Entolimod, a pharmacologically optimized flagellin derivative, was initially developed to treat and prevent acute radiation syndrome with demonstrated efficacy in rodents and non-human primates and safety in human healthy volunteers. In addition, Entolimod demonstrated antitumor effects in mouse models of uveal melanoma, lymphoma, breast, and colorectal carcinoma. Entolimod’s mechanism of action involves activation of NF-κB-, AP-1-, and STAT-3-driven immunomodulatory pathways in hepatocytes that initiates a cascade of cell-cell signaling events that mobilize innate and adaptive immunity to the liver. This includes CXCR3-dependent blood-borne NK cell homing followed by DC activation and antitumor CD8+ T cell memory formation. These results define systemically administered TLR5 agonists as an organ-specific immunoadjuvant enabling efficient antitumor vaccination that does not depend on identification of tumor-specific antigens. Therefore, Entolimod has strong promise as a safe, effective and broadly applicable immunotherapeutic agent against liver metastases, which are currently a major cause of cancer-associated mortality. Recent completion of a phase I trial of Entolimod in patients with advanced metastatic solid tumors has opened the opportunity to test whether efficacy demonstrated in animal cancer models could be translated into immunotherapy of human tumors." @default.
- W4313360294 created "2023-01-06" @default.
- W4313360294 creator A5038923700 @default.
- W4313360294 creator A5053311556 @default.
- W4313360294 creator A5058401562 @default.
- W4313360294 creator A5069808553 @default.
- W4313360294 creator A5082241355 @default.
- W4313360294 creator A5087204160 @default.
- W4313360294 date "2016-05-01" @default.
- W4313360294 modified "2023-09-23" @default.
- W4313360294 title "The clinical-stage TLR5 agonist, Entolimod, mediates antimetastatic activity by stimulating a CXCR3-dependent NK-DC-CD8+ T cell axis" @default.
- W4313360294 doi "https://doi.org/10.4049/jimmunol.196.supp.75.5" @default.
- W4313360294 hasPublicationYear "2016" @default.
- W4313360294 type Work @default.
- W4313360294 citedByCount "0" @default.
- W4313360294 crossrefType "journal-article" @default.
- W4313360294 hasAuthorship W4313360294A5038923700 @default.
- W4313360294 hasAuthorship W4313360294A5053311556 @default.
- W4313360294 hasAuthorship W4313360294A5058401562 @default.
- W4313360294 hasAuthorship W4313360294A5069808553 @default.
- W4313360294 hasAuthorship W4313360294A5082241355 @default.
- W4313360294 hasAuthorship W4313360294A5087204160 @default.
- W4313360294 hasConcept C12823836 @default.
- W4313360294 hasConcept C13373296 @default.
- W4313360294 hasConcept C136449434 @default.
- W4313360294 hasConcept C167672396 @default.
- W4313360294 hasConcept C193419808 @default.
- W4313360294 hasConcept C203014093 @default.
- W4313360294 hasConcept C25532541 @default.
- W4313360294 hasConcept C2776090121 @default.
- W4313360294 hasConcept C2776709828 @default.
- W4313360294 hasConcept C2777338127 @default.
- W4313360294 hasConcept C2777701055 @default.
- W4313360294 hasConcept C2778170410 @default.
- W4313360294 hasConcept C2780674031 @default.
- W4313360294 hasConcept C502942594 @default.
- W4313360294 hasConcept C71924100 @default.
- W4313360294 hasConcept C86803240 @default.
- W4313360294 hasConcept C8891405 @default.
- W4313360294 hasConceptScore W4313360294C12823836 @default.
- W4313360294 hasConceptScore W4313360294C13373296 @default.
- W4313360294 hasConceptScore W4313360294C136449434 @default.
- W4313360294 hasConceptScore W4313360294C167672396 @default.
- W4313360294 hasConceptScore W4313360294C193419808 @default.
- W4313360294 hasConceptScore W4313360294C203014093 @default.
- W4313360294 hasConceptScore W4313360294C25532541 @default.
- W4313360294 hasConceptScore W4313360294C2776090121 @default.
- W4313360294 hasConceptScore W4313360294C2776709828 @default.
- W4313360294 hasConceptScore W4313360294C2777338127 @default.
- W4313360294 hasConceptScore W4313360294C2777701055 @default.
- W4313360294 hasConceptScore W4313360294C2778170410 @default.
- W4313360294 hasConceptScore W4313360294C2780674031 @default.
- W4313360294 hasConceptScore W4313360294C502942594 @default.
- W4313360294 hasConceptScore W4313360294C71924100 @default.
- W4313360294 hasConceptScore W4313360294C86803240 @default.
- W4313360294 hasConceptScore W4313360294C8891405 @default.
- W4313360294 hasIssue "1_Supplement" @default.
- W4313360294 hasLocation W43133602941 @default.
- W4313360294 hasOpenAccess W4313360294 @default.
- W4313360294 hasPrimaryLocation W43133602941 @default.
- W4313360294 hasRelatedWork W1556307916 @default.
- W4313360294 hasRelatedWork W1557621914 @default.
- W4313360294 hasRelatedWork W1984674482 @default.
- W4313360294 hasRelatedWork W1994960978 @default.
- W4313360294 hasRelatedWork W2103515427 @default.
- W4313360294 hasRelatedWork W2141330728 @default.
- W4313360294 hasRelatedWork W2946615038 @default.
- W4313360294 hasRelatedWork W2971006194 @default.
- W4313360294 hasRelatedWork W3018388059 @default.
- W4313360294 hasRelatedWork W4206425682 @default.
- W4313360294 hasVolume "196" @default.
- W4313360294 isParatext "false" @default.
- W4313360294 isRetracted "false" @default.
- W4313360294 workType "article" @default.